集体诉讼案件 - 投资者针对Elevance Health公司提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼涉及2024年4月18日至2024年10月16日期间购买公司证券的股东 [1] - 公司被指控在Medicaid成员健康程度和利用率方面做出虚假和误导性陈述 [1] 诉讼指控内容 - 公司未如实披露因Medicaid资格重审导致的成员健康结构变化 [1] - 实际发生的利用率变化未体现在与各州的费率谈判中 [1] - 公司向投资者提供的财务指引未反映上述变化 [1] 法律事务信息 - 律师事务所提醒受损股东需在2025年7月11日前联系参与诉讼 [1] - 该律所专注于证券集体诉讼和公司治理诉讼 [3] - 律所客户包括大型对冲基金和另类资产管理机构 [3]

集体诉讼案件 - 罗森律师事务所提醒在2024年4月18日至2024年10月16日期间购买Elevance Health公司普通股的投资者注意2025年7月11日的首席原告截止日期 [1] - 投资者可能有权通过应急费用安排获得补偿而无需支付任何自付费用 [1] - 集体诉讼已经提起，希望担任首席原告的投资者需在2025年7月11日前向法院提出申请 [2] 诉讼详情 - 指控Elevance Health在2024年 Medicaid重新确定过程中向投资者做出虚假或误导性陈述 [4] - 公司声称密切监控与重新确定过程相关的成本趋势，并确保与各州协商的保费费率足以应对 Medicaid 计划中患者的风险和成本状况 [4] - 实际情况是 Medicaid 重新确定导致成员的健康状况和利用率显著上升，因为被移除 Medicaid 计划的成员平均比仍符合资格的健康 [4] - 这种变化程度未反映在公司与各州的费率谈判或2024年财务指引中，导致投资者遭受损失 [4] 律师事务所背景 - 罗森律师事务所在证券集体诉讼和股东衍生诉讼方面具有专长 [3] - 该事务所曾创下针对中国公司的最大证券集体诉讼和解记录 [3] - 2017年被ISS证券集体诉讼服务评为证券集体诉讼和解数量第一名 [3] - 自2013年以来每年排名前四，已为投资者追回数亿美元 [3] - 2019年单独为投资者获得超过4.38亿美元 [3]

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP宣布对Elevance Health Inc及其高管提起联邦证券法诉讼 [1] - 诉讼依据《1934年证券交易法》第10(b)和20(a)条款 代表购买Elevance普通股的投资人 [2] - 案件编号为Miller v Elevance Health Inc et al No 25-cv-0092 由美国印第安纳南区地方法院受理 [2] 诉讼核心指控 - Elevance主营医疗保险业务 包括与各州签订管理Medicaid福利的合同 [3] - 公司声称密切监控Medicaid资格重审过程的成本趋势 并称协商费率足以覆盖参保人群风险 [4] - 实际重审导致Medicaid参保成员医疗需求和利用率显著上升 但该变化未体现在费率协商或2024年财务指引中 [5] 股价波动事件 - 2024年7月17日公司预警Medicaid利用率上升 股价单日下跌32.21美元(6%) 从553.14美元跌至520.93美元 [6] - 2024年10月17日Q3财报显示因Medicaid业务医疗成本超预期 EPS较共识低1.33美元(13.7%) 股价单日下跌52.61美元(11%) 从496.96美元跌至444.35美元 [7] 律所背景 - Bleichmar Fonti & Auld LLP是专业证券集体诉讼律所 2023年被ISS SCAS评为全美前五大原告律所 [11] - 该律所近期成功案例包括从特斯拉董事会追回9亿美元 从Teva制药追回4.2亿美元 [11]

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

PHILADELPHIA, May 29, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repre ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

Shares of Elevance Health (NYSE: ELV ) have fallen 27% over the past year and the stock has meaningfully underperformed the broader market ( SPY ) over the past 1, 3, and 5 years. While there are reasons for this underperformance whichAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ELV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). ...

BENSALEM, Pa., May 28, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ELEVANCE HEALTH, INC. (ELV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices o ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Elevance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

估值分析 - 公司当前12个月前瞻市盈率仅为10.35倍 显著低于五年中位数13.46倍和行业平均13.86倍 [1] - 相比同业公司UnitedHealth(12.06倍)和Humana(14.73倍) 估值更具吸引力 [1] - 获得Zacks价值评分A级 凸显估值基本面优势 [1] 业务增长驱动 - 商业保险业务稳健增长 2024年风险型和费用型会员数同比分别增长4.6%和1% [4] - 个人商业保险业务表现突出 2025年一季度单季增长14.2% [4] - 政府业务通过退出低效市场实现优化 在渗透不足州份的Medicare Advantage业务存在扩张空间 [5] - 牙科和视力保险会员保持增长势头 [5] 财务指标 - 投资资本回报率达9.94% 远超行业平均5.79% [6] - 市值841亿美元 具备规模优势推动高毛利业务并购 [6] - 2025年一季度回购8.8亿美元股票 剩余授权回购额度84亿美元 [7] - 股息收益率1.82% 高于行业平均1.40% [7] 市场表现 - 年内股价上涨1.9% 跑赢行业指数和标普500指数 [8] - 同业公司UnitedHealth和Humana同期股价下跌 [8] 盈利预测 - 2025年和2026年EPS共识预期同比增幅分别为4.2%和13.8% [11] - 同期营收预期增幅为11.2%和7.1% [11] - 过去四个季度中有三次盈利超预期 [11] 业务挑战 - Medicaid和Medicare Supplement会员数量下降导致总收入减少 [12] - 医疗福利支出比率从2023年87%升至2024年88.5% 预计2025年达88.7% [13] - 药品福利管理业务面临特朗普政府"最惠国"药价政策不确定性 [14]